RxDoctor Payments Data

Georgia Willie-Carnegie, MD

Cardiovascular Disease · Washington, DCNPI 1730298845

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations.

$6,166in general payments, 2019–2025

Across 235 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$912
  • Amgen$619
  • Medtronic$613
  • Alnylam Pharmaceuticals Inc.$480
  • Novartis$440
  • Gilead$345
  • plus $3K from 28 others
$4,695in research payments, 2019–2025

Across 2 payments — averaging $2347.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$5K

What the payments were for

  • Food & beverage$6,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,166 in reported general payments places this provider in the 70th percentile of 105 cardiovascular disease providers in District of Columbia.

See all cardiovascular disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$197,590
Medicare patients
1,011
Services billed
2,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$106,255
EntrestoSacubitril/Valsartan109$94,942
XareltoRivaroxaban42$52,730
JardianceEmpagliflozin40$29,002
BrilintaTicagrelor14$10,201
Ranolazine ErRanolazine49$5,768
Metoprolol Succinate335$3,583
Valsartan56$2,650
Nifedipine ErNifedipine101$2,229
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$2,216
Nebivolol Hcl30$1,342
Isosorbide Mononitrate ErIsosorbide Mononitrate122$1,214
Furosemide219$1,106
Rosuvastatin Calcium60$1,023
Atorvastatin Calcium135$990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$235$106,255142 claims
NovartisEntresto$440$94,942109 claims
Johnson & JohnsonXarelto$173$52,73042 claims
Boehringer IngelheimJardiance$217$29,00240 claims
AstraZenecaBrilinta$157$10,20114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 105 cardiovascular disease providers in District of Columbia.

Other cardiovascular disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →